Journal of Translational Medicine (Jul 2018)

Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients

  • Shou-Sheng Liu,
  • Yuan-Zhong Yang,
  • Chang Jiang,
  • Qi Quan,
  • Qian-Kun Xie,
  • Xiao-Pai Wang,
  • Wen-Zhuo He,
  • Yu-Ming Rong,
  • Ping Chen,
  • Qiong Yang,
  • Lin Yang,
  • Bei Zhang,
  • Xiao-Jun Xia,
  • Peng-Fei Kong,
  • Liang-Ping Xia

DOI
https://doi.org/10.1186/s12967-018-1570-z
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Currently, mismatch repair-deficient (dMMR) status is a promising candidate for targeted immune checkpoint inhibition therapy in colorectal cancer (CRC) patients, however, the potential immunological mechanism has not yet been well clarified and some other predictors need to be excavated as well. Methods We collected 330 CRC patients by the match of mismatch repair-proficient (167) and dMMR (163), explored the relationship between MMR status and some important immune molecules including MHC class I, CD3, CD4, CD8, CD56, programmed death-1 and programmed death ligand-1, and investigated the risk factors for dMMR status as well as low MHC class I expression. The Pearson Chi square test was used for analyzing the associations between clinicopathological and immune characteristics and MMR status, and two categories logistic regression model was used for univariate and multivariate analysis to predict the odds ratio of risk factors for dMMR status and low MHC class I expression. Results Multivariate logistic regression analysis showed that low MHC class I and CD4 expression and high CD8 expression were significant risk factors for dMMR status [odds ratio (OR) = 24.66, 2.94 and 2.97, respectively; all p < 0.05] and dMMR status was the only risk factor for low MHC class I expression (OR = 15.34; p < 0.001). Conclusions High CD8 and low MHC class I expression suggests the contradiction and complexity of immune microenvironment in dMMR CRC patients. Some other immunocytes such as CD56+ cells might also participate in the process of immune checkpoint inhibition, whereas needs further investigations.

Keywords